nach oben

Drug Safety

Erschienen in:

01.02.2012 | Systematic Review

Methods for Assessing the Preventability of Adverse Drug Events

A Systematic Review

verfasst von: Katja Marja Hakkarainen, Karolina Andersson Sundell, Max Petzold, Staffan Hägg

Erschienen in: Drug Safety | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Background: Preventable adverse drug events (ADEs) are common in both outpatient and inpatient settings. However, the proportion of preventable ADEs varies considerably in different studies, even when conducted in the same setting, and methods for assessing the preventability of ADEs are diverse.

Objective: The aim of this article is to identify and systematically evaluate methods for assessing the preventability of ADEs.

Data sources: Seven databases (Cochrane, CINAHL, EMBASE, IPA, MEDLINE, PsycINFO and Web of Science) were searched in September 2010 utilizing the databases’ index terms and other common terminology on preventable ADEs. No limits for the years of publication were set. Reference lists of included original articles and relevant review articles were also screened.

Study selection: After applying predetermined inclusion and exclusion criteria on 4161 unique citations, 142 (3.4%) original research articles were included in the review. One additional article was included from reference lists. Outcome measures of included studies had to include the frequency of ADEs and the assessment of their preventability. Studies were excluded if they focused on individuals with one specific type of treatment, medical condition, medical procedure or ADE.

Data extraction: Measurement instruments for determining the preventability of ADEs in each article were extracted and unique instruments were compared. The process of assessing the preventability of ADEs was described based on reported actions taken to standardize and conduct the assessment, and on information about the reliability and validity of the assessment.

Data synthesis: Eighteen unique instruments for determining the preventability of ADEs were identified. They fell under the following four groups: (i) instruments using a definition of preventability only (n=3); (ii) instruments with a definition of preventability and an assessment scale for determining preventability (n=5); (iii) instruments with specific criteria for each preventability category (n=3); and (iv) instruments with an algorithm for determining preventability (n=7). Of actions to standardize the assessment process, performing a pilot study was reported in 21 (15%), and use of a standardized protocol was reported in 18 (13%), of the included 143 articles. Preventability was assessed by physicians in 86 (60%) articles and by pharmacists in 41 (29%) articles. In 29 (20%) articles, persons conducting the assessment were described as trained for or experienced in preventability assessment. In 94 (66%) articles, more than one person assessed the preventability of each case. Among these 94 articles, assessment was done independently in 73 (51%) articles. Procedures for managing conflicting assessments were diverse. The reliability of the preventability assessment was tested in 39 (27%) articles, and 16 (11%) articles referred to a previous reliability assessment. Reliability ranged from poor to excellent (kappa 0.19–0.98; overall agreement 26–97%). Four (3%) articles mentioned assessing validity, but no sensitivity or specificity analyses or negative or positive predictive values were presented.

Conclusions: Instruments for assessing the preventability of ADEs vary from implicit instruments to explicit algorithms. There is limited evidence for the validity of the identified instruments, and instrument reliability varied significantly. The process of assessing the preventability of ADEs is also commonly imprecisely described, which hinders the interpretation and comparison of studies. For measuring the preventability of ADEs more accurately and precisely in future, we believe that existing instruments should be further studied and developed, or that one or more new instruments should be developed, and the validity and reliability of the existing and new instruments be established.

Nur mit Berechtigung zugänglich

de Vries EN, Ramrattan MA, Smorenburg SM, et al. The incidence and nature of in-hospital adverse events: a systematic review. Qual Saf Health Care 2008; 17(3): 216–23PubMed

Masotti P, McColl MA, Green M. Adverse events experienced by homecare patients: a scoping review of the literature. Int J Qual Health Care 2010; 22(2): 115–25PubMed

Morimoto T, Gandhi TK, Seger AC, et al. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care 2004; 13(4): 306–14PubMed

Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2007; 63(2): 136–47PubMed

Thomsen LA, Winterstein AG, Sondergaard B, et al. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother 2007; 41(9): 1411–26PubMed

Krahenbuhl-Melcher A, Schlienger R, Lampert M, et al. Drug-related problems in hospitals: a review of the recent literature. Drug Saf 2007; 30(5): 379–407PubMed

Kanjanarat P, Winterstein AG, Johns TE, et al. Nature of preventable adverse drug events in hospitals: a literature review. Am J Health Syst Pharm 2003; 60(17): 1750–9PubMed

Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. ADE Prevention Study Group. JAMA 1995; 274(1): 29–34PubMed

Cullen DJ, Bates DW, Small SD, et al. The incident reporting system does not detect adverse drug events: a problem for quality improvement. Jt Comm J Qual Improv 1995; 21(10): 541–8PubMed

10.

van Doormaal JE, Mol PG, van den Bemt PM, et al. Reliability of the assessment of preventable adverse drug events in daily clinical practice. Pharmacoepidemiol Drug Saf 2008; 17(7): 645–54PubMed

11.

Ferner RE, Aronson JK. Preventability of drug-related harms, part I: a systematic review. Drug Saf 2010; 33(11): 985–94PubMed

12.

Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med 1997; 157(14): 1531–6PubMed

13.

Even in best-run centers, preventable medication errors lengthen LOS, increase costs. Health Care Cost Reengineering Rep 1998; 3(10): 149–51

14.

Bell D. Cooperative approach to medication errors. Sth Hosp 1974; 42(9): 12–20

15.

Hulley SB, Martin JN, Cummings SR. Planning the measurement: precision and accuracy. In: Hulley SB, Cummings SR, Browner WS, et al., editors. Designing clinical research. 3rd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2007: 37–50

16.

Streiner DL, Norman GR. Reliability. In: Streiner DL, Norman GR, editors. Health measurement scales-a practical guide to their development and use. 3rd ed. New York: Oxford University Press, 2003: 126–52

17.

Streiner DL, Norman GR. Validity. In: Streiner DL, Norman GR, editors. Health measurement scales-a practical guide to their development and use. 3rd ed. New York: Oxford University Press, 2003: 173–93

18.

van der Hooft CS, Dieleman JP, Siemes C, et al. Adverse drug reaction-related hospitalisations: a population-based cohort study. Pharmacoepidemiol Drug Saf 2008; 17(4): 365–71PubMed

19.

Olivier P, Boulbes O, Tubery M, et al. Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice: a study in a French emergency department. Drug Saf 2002; 25(14): 1035–44PubMed

20.

Letrilliart L, Hanslik T, Biour M, et al. Postdischarge adverse drug reactions in primary care originating from hospital care in France: a nationwide prospective study. Drug Saf 2001; 24(10): 781–92PubMed

21.

Calderon-Ospina C, Bustamante-Rojas C. The DoTS classification is a useful way to classify adverse drug reactions: a preliminary study in hospitalized patients. Int J Pharm Pract 2010; 18(4): 230–5PubMed

22.

Farcas A, Sinpetrean A, Mogosan C, et al. Adverse drug reactions detected by stimulated spontaneous reporting in an internal medicine department in Romania. Eur J Intern Med 2010; 21(5): 453–7PubMed

23.

Jönsson AK, Hakkarainen KM, Spigset O, et al. Preventable drug related mortality in a Swedish population. Pharmacoepidemiol Drug Saf 2010; 19(2): 211–5PubMed

24.

Lopez LC, Botero M, Pino J, et al. Adverse drug reactions in internal medicine units at a university hospital: a descriptive pilot study. Colomb Medica 2010; 41(1): 45–51

25.

Davies EC, Green CF, Taylor S, et al. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 2009; 4(2): e4439PubMed

26.

Pourseyed S, Fattahi F, Pourpak Z, et al. Adverse drug reactions in patients in an Iranian department of internal medicine. Pharmacoepidemiol Drug Saf 2009; 18(2): 104–10PubMed

27.

Alexopoulou A, Dourakis SP, Mantzoukis D, et al. Adverse drug reactions as a cause of hospital admissions: a 6-month experience in a single center in Greece. Eur J Intern Med 2008; 19(7): 505–10PubMed

28.

Al-Malaq HM, Al-Aqeel SA, Al-Sultan MS. Adverse drug reactions related hospitalization identified by discharge ICD-9 codes in a university hospital in Riyadh. Saudi Med J 2008; 29(8): 1145–50PubMed

29.

Baniasadi S, Fahimi F, Shalviri G. Developing an adverse drug reaction reporting system at a teaching hospital. Basic Clin Pharmacol Toxicol 2008; 102(4): 408–11PubMed

30.

Franceschi M, Scarcelli C, Niro V, et al. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients. Drug Saf 2008; 31(6): 545–56PubMed

31.

Hopf Y, Watson M, Williams D. Adverse-drug-reaction related admissions to a hospital in Scotland. Pharm World Sci 2008; 30(6): 854–62PubMed

32.

Joshua L, Devi P, Guido S. Adverse drug reactions in medical intensive care unit of a tertiary care hospital. Pharmacoepidemiol Drug Saf 2009; 18(7): 639–45PubMed

33.

Mehta U, Durrheim DN, Blockman M, et al. Adverse drug reactions in adult medical inpatients in a South African hospital serving a community with a high HIV/AIDS prevalence: prospective observational study. Br J Clin Pharmacol 2008; 65(3): 396–406PubMed

34.

Ruiz B, Garcia M, Aguirre U, et al. Factors predicting hospital readmissions related to adverse drug reactions. Eur J Clin Pharmacol 2008; 64(7): 715–22PubMed

35.

Subish P, Mishra P, Shankar PR. Systemic adverse drug reactions: a preliminary report from the regional pharmacovigilance center, western Nepal. Pak J Pharm Sci 2008; 21(4): 465–7

36.

Grenouillet-Delacre M, Verdoux H, Moore N, et al. Life-threatening adverse drug reactions at admission to medical intensive care: a prospective study in a teaching hospital. Intensive Care Med 2007; 33(12): 2150–7PubMed

37.

Patel KJ, Kedia MS, Bajpai D, et al. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC Clin Pharmacol 2007; 7: 8PubMed

38.

Rivkin A. Admissions to a medical intensive care unit related to adverse drug reactions. Am J Health Syst Pharm 2007; 64(17): 1840–3PubMed

39.

Davies EC, Green CF, Mottram DR, et al. Adverse drug reactions in hospital in-patients: a pilot study. J Clin Pharm Ther 2006; 31(4): 335–41PubMed

40.

Hanlon JT, Pieper CF, Hajjar ER, et al. Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay. J Gerontol A Biol Sci Med Sci 2006; 61(5): 511–5PubMed

41.

Jose J, Rao PG. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital. Pharmacol Res 2006; 54(3): 226–33PubMed

42.

Dormann H, Neubert A, Criegee-Rieck M, et al. Readmissions and adverse drug reactions in internal medicine: the economic impact. J Intern Med 2004; 255(6): 653–63PubMed

43.

Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329(7456): 15–9PubMed

44.

Temple ME, Robinson RF, Miller JC, et al. Frequency and preventability of adverse drug reactions in paediatric patients. Drug Saf 2004; 27(11): 819–29PubMed

45.

Dormann H, Criegee-Rieck M, Neubert A, et al. Lack of awareness of community-acquired adverse drug reactions upon hospital admission: dimensions and consequences of a dilemma. Drug Saf 2003; 26(5): 353–62PubMed

46.

Easton-Carter KL, Chapman CB, Brien JE. Adverse drug reactions in paediatrics: are we getting the full picture? J Pharm Res 2003; 33(2): 106–10

47.

Easton-Carter KL, Chapman CB, Brien JE. Emergency department attendances associated with drug-related problems in paediatrics. J Paediatr Child Health 2003; 39(2): 124–9PubMed

48.

McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2002; 36(9): 1331–6PubMed

49.

Wasserfallen J, Livio F, Buclin T, et al. Rate, type, and cost of adverse drug reactions in emergency department admissions. Eur J Intern Med 2001; 12(5): 442–7PubMed

50.

Lagnaoui R, Moore N, Fach J, et al. Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability. Eur J Clin Pharmacol 2000; 56(2): 181–6PubMed

51.

Gholami K, Shalviri G. Factors associated with preventability, predictability, and severity of adverse drug reactions. Ann Pharmacother 1999; 33(2): 236–40PubMed

52.

Schumock GT, Seeger JD, Kong SX. Control charts to monitor rates of adverse drug reactions. Hosp Pharm 1995; 30(12): 1088, 1091–2, 1095–6PubMed

53.

Pearson TF, Pittman DG, Longley JM, et al. Factors associated with preventable adverse drug reactions. Am J Hosp Pharm 1994; 51(18): 2268–72PubMed

54.

Kramer MS, Hutchinson TA, Flegel KM, et al. Adverse drug reactions in general pediatric outpatients. J Pediatr 1985; 106(2): 305–10PubMed

55.

Choonara IA, Harris F. Adverse drug reactions in medical inpatients. Arch Dis Child 1984; 59(6): 578–80PubMed

56.

Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med 1993; 8(6): 289–94PubMed

57.

Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001; 285(16): 2114–20PubMed

58.

Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med 2003; 348(16): 1556–64PubMed

59.

Winterstein AG, Hatton RC, Gonzalez-Rothi R, et al. Identifying clinically significant preventable adverse drug events through a hospital’s database of adverse drug reaction reports. Am J Health Syst Pharm 2002; 59(18): 1742–9PubMed

60.

Gray SL, Sager M, Lestico MR, et al. Adverse drug events in hospitalized elderly. J Gerontol A Biol Sci Med Sci 1998; 53(1): M59–63PubMed

61.

Leape LL, Bates DW, Cullen DJ, et al. Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA 1995; 274(1): 35–43PubMed

62.

Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997; 277(4): 307–11PubMed

63.

Cullen DJ, Sweitzer BJ, Bates DW, et al. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med 1997; 25(8): 1289–97PubMed

64.

Bates DW, Leape LL, Cullen DJ, et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA 1998; 280(15): 1311–6PubMed

65.

Jha AK, Kuperman GJ, Teich JM, et al. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc 1998; 5(3): 305–14PubMed

66.

Bates DW, Miller EB, Cullen DJ, et al. Patient risk factors for adverse drug events in hospitalized patients. ADE Prevention Study Group. Arch Intern Med 1999; 159(21): 2553–60PubMed

67.

Bates DW, Teich JM, Lee J, et al. The impact of computerized physician order entry on medication error prevention. J Am Med Inform Assoc 1999; 6(4): 313–21PubMed

68.

Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA 1999; 282(3): 267–70PubMed

69.

Honigman B, Lee J, Rothschild J, et al. Using computerized data to identify adverse drug events in outpatients. J Am Med Inform Assoc 2001; 8(3): 254–66PubMed

70.

Gurwitz JH, Field TS, Harrold LR, et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003; 289(9): 1107–16PubMed

71.

Field TS, Gurwitz JH, Harrold LR, et al. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc 2004; 52(8): 1349–54PubMed

72.

Field TS, Gurwitz JH, Harrold LR, et al. Strategies for detecting adverse drug events among older persons in the ambulatory setting. J Am Med Inform Assoc 2004; 11(6): 492–8PubMed

73.

Field TS, Gilman BH, Subramanian S, et al. The costs associated with adverse drug events among older adults in the ambulatory setting. Med Care 2005; 43(12): 1171–6PubMed

74.

Kopp BJ, Erstad BL, Allen ME, et al. Medication errors and adverse drug events in an intensive care unit: direct observation approach for detection. Crit Care Med 2006; 34(2): 415–25PubMed

75.

Field TS, Mazor KM, Briesacher B, et al. Adverse drug events resulting from patient errors in older adults. J Am Geriatr Soc 2007; 55(2): 271–6PubMed

76.

Kaushal R, Goldmann DA, Keohane CA, et al. Adverse drug events in pediatric outpatients. Ambul Pediatr 2007; 7(5): 383–9PubMed

77.

Wang JK, Herzog NS, Kaushal R, et al. Prevention of pediatric medication errors by hospital pharmacists and the potential benefit of computerized physician order entry. Pediatrics 2007; 119(1): e77–85PubMed

78.

Zandieh SO, Goldmann DA, Keohane CA, et al. Risk factors in preventable adverse drug events in pediatric outpatients. J Pediatr 2008; 152(2): 225–31PubMed

79.

Takata GS, Taketomo CK, Waite S, et al. Characteristics of medication errors and adverse drug events in hospitals participating in the California Pediatric Patient Safety Initiative. Am J Health Syst Pharm 2008; 65(21): 2036–44PubMed

80.

Forster AJ, Halil RB, Tierney MG. Pharmacist surveillance of adverse drug events. Am J Health Syst Pharm 2004; 61(14): 1466–72PubMed

81.

Franklin BD, Birch S, Schachter M, et al. Testing a trigger tool as a method of detecting harm from medication errors in a UK hospital: a pilot study. Int J Pharm Pract 2010; 18(5): 305–11PubMed

82.

Hug BL, Witkowski DJ, Sox CM, et al. Adverse drug event rates in six community hospitals and the potential impact of computerized physician order entry for prevention. J Gen Intern Med 2010; 25(1): 31–8PubMed

83.

Benkirane R, Pariente A, Achour S, et al. Prevalence and preventability of adverse drug events in a teaching hospital: a cross-sectional study. East Mediterr Health J 2009; 15(5): 1145–55PubMed

84.

Benkirane RR, Abouqal R, Haimeur CC, et al. Incidence of adverse drug events and medication errors in intensive care units: a prospective multicenter study. J Patient Saf 2009; 5(1): 16–22PubMed

85.

Kunac DL, Kennedy J, Austin N, et al. Incidence, preventability, and impact of adverse drug events (ADEs) and potential ADEs in hospitalized children in New Zealand: a prospective observational cohort study. Paediatr Drugs 2009; 11(2): 153–60PubMed

86.

Gurwitz JH, Field TS, Rochon P, et al. Effect of computerized provider order entry with clinical decision support on adverse drug events in the long-term care setting. J Am Geriatr Soc 2008; 56(12): 2225–33PubMed

87.

Hwang SH, Lee S, Koo HK, et al. Evaluation of a computer-based adverse-drug-event monitor. Am J Health Syst Pharm 2008; 65(23): 2265–72PubMed

88.

Jha AK, Laguette J, Seger A, et al. Can surveillance systems identify and avert adverse drug events? A prospective evaluation of a commercial application. J Am Med Informatics Assoc 2008; 15(5): 647–53

89.

Kaushal R, Bates DW, Abramson EL, et al. Unit-based clinical pharmacists’ prevention of serious medication errors in pediatric inpatients. Am J Health Syst Pharm 2008; 65(13): 1254–60PubMed

90.

Koneri R, Prakasam K, Mishra V, et al. Drug-related hospitalizations at a tertiary level hospital in Bangalore: a prospective study. J Clin Diagn Res 2008; 2(2): 736–40

91.

Kunac DL, Reith DM. Preventable medication-related events in hospitalised children in New Zealand. N Z Med J 2008; 121(1272): 17–32PubMed

92.

Saha L, Pandhi P, Malhotra S, et al. Adverse Drug Event (ADE) related medical emergency department visits and hospital admissions: a prospective study from a north India referral India. J Clin Diagn Res 2008; 2(1): 600–4

93.

Takata GS, Mason W, Taketomo C, et al. Development, testing, and findings of a pediatric-focused trigger tool to identify medication-related harm in US children’s hospitals. Pediatrics 2008; 121(4): e927–35PubMed

94.

Tam KW, Kwok KH, Fan YM, et al. Detection and prevention of medication misadventures in general practice. Int J Qual Health Care 2008; 20(3): 192–9PubMed

95.

Glassman PA, Belperio P, Lanto A, et al. The utility of adding retrospective medication profiling to computerized provider order entry in an ambulatory care population. J Am Med Inform Assoc 2007; 14(4): 424–31PubMed

96.

Holdsworth MT, Fichtl RE, Raisch DW, et al. Impact of computerized prescriber order entry on the incidence of adverse drug events in pediatric inpatients. Pediatrics 2007; 120(5): 1058–66PubMed

97.

Queneau P, Bannwarth B, Carpentier F, et al. Emergency department visits caused by adverse drug events: results of a French survey. Drug Saf 2007; 30(1): 81–8PubMed

98.

Seger AC, Jha AK, Bates DW. Adverse drug event detection in a community hospital utilising computerised medication and laboratory data. Drug Saf 2007; 30(9): 817–24PubMed

99.

Kane-Gill S, Rea RS, Verrico MM, et al. Adverse-drug-event rates for high-cost and high-use drugs in the intensive care unit. Am J Health Syst Pharm 2006; 63(19): 1876–81PubMed

100.

Miller GC, Britth HC, Valenti L. Adverse drug events in general practice patients in Australia. Med J Aust 2006; 184(7): 321–4PubMed

101.

Schade CP, Hannah K, Ruddick P, et al. Improving self-reporting of adverse drug events in a West Virginia hospital. Am J Med Qual 2006; 21(5): 335–41PubMed

102.

Schnipper JL, Kirwin JL, Cotugno MC, et al. Role of pharmacist counseling in preventing adverse drug events after hospitalization. Arch Intern Med 2006; 166(5): 565–71PubMed

103.

Walsh KE, Adams WG, Bauchner H, et al. Medication errors related to computerized order entry for children. Pediatrics 2006; 118(5): 1872–9PubMed

104.

Al-Tajir GK, Kelly WN. Epidemiology, comparative methods of detection, and preventability of adverse drug events. Ann Pharmacother 2005; 39(7–8): 1169–74PubMed

105.

Forster AJ, Murff HJ, Peterson JF, et al. Adverse drug events occurring following hospital discharge. J Gen Intern Med 2005; 20(4): 317–23PubMed

106.

Gurwitz JH, Field TS, Judge J, et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med 2005; 118(3): 251–8PubMed

107.

Mycyk MB, McDaniel MR, Fotis MA, et al. Hospital wide adverse drug events before and after limiting weekly work hours of medical residents to 80. Am J Health Syst Pharm 2005; 62(15): 1592–5PubMed

108.

Weingart SN, Gandhi TK, Seger AC, et al. Patientreported medication symptoms in primary care. Arch Intern Med 2005; 165(2): 234–40PubMed

109.

Hardmeier B, Braunschweig S, Cavallaro M, et al. Adverse drug events caused by medication errors in medical inpatients. Swiss Med Wkly 2004; 134(45–46): 664–70PubMed

110.

Holdsworth MT, Fichtl RE, Behta M, et al. Incidence and impact of adverse drug events in pediatric inpatients. Arch Pediatr Adolesc Med 2003; 157(1): 60–5PubMed

111.

Peyriere H, Cassan S, Floutard E, et al. Adverse drug events associated with hospital admission. Ann Pharmacother 2003; 37(1): 5–11PubMed

112.

Chan M, Nicklason F, Vial JH. Adverse drug events as a cause of hospital admission in the elderly. Intern Med J 2001; 31(4): 199–205PubMed

113.

Jha AK, Kuperman GJ, Rittenberg E, et al. Identifying hospital admissions due to adverse drug events using a computer-based monitor. Pharmacoepidemiol Drug Saf 2001; 10(2): 113–9PubMed

114.

Malhotra S, Jain S, Pandhi P. Drug-related visits to the medical emergency department: a prospective study from India. Int J Clin Pharmacol Ther 2001; 39(1): 12–8PubMed

115.

Senst BL, Achusim LE, Genest RP, et al. Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health Syst Pharm 2001; 58(12): 1126–32PubMed

116.

Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000; 109(2): 87–94PubMed

117.

Raschetti R, Morgutti M, Menniti-Ippolito F, et al. Suspected adverse drug events requiring emergency department visits or hospital admissions. Eur J Clin Pharmacol 1999; 54(12): 959–63PubMed

118.

Bates DW, Boyle DL, Vander Vliet MB, et al. Relationship between medication errors and adverse drug events. J Gen Intern Med 1995; 10(4): 199–205PubMed

119.

Thomas EJ, Orav EJ, Brennan TA. Hospital ownership and preventable adverse events. Int J Health Serv 2000; 30(4): 745–61PubMed

120.

Buckley MS, Erstad BL, Kopp BJ, et al. Direct observation approach for detecting medication errors and adverse drug events in a pediatric intensive care unit. Pediatr Crit Care Med 2007; 8(2): 145–52PubMed

121.

Ligi I, Arnaud F, Jouve E, et al. Iatrogenic events in admitted neonates: a prospective cohort study. Lancet 2008; 371(9610): 404–10PubMed

122.

Leape LL, Lawthers AG, Brennan TA, et al. Preventing medical injury. QRB Qual Rev Bull 1993; 19(5): 144–9PubMed

123.

Forster AJ, Murff HJ, Peterson JF, et al. The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med 2003; 138(3): 161–7PubMed

124.

Agarwal S, Classen D, Larsen G, et al. Prevalence of adverse events in pediatric intensive care units in the United States. Pediatr Crit Care Med 2010; 11(5): 568–78PubMed

125.

Mercier E, Giraudeau B, Ginies G, et al. Iatrogenic events contributing to ICU admission: a prospective study. Intensive Care Med 2010; 36(6): 1033–7PubMed

126.

Aranaz-Andres J, Aibar-Remon C, Vitaller-Murillo J, et al. Incidence of adverse events related to health care in Spain: Results of the Spanish National Study of Adverse Events. J Epidemiol Community Health 2008; 62(12): 1022–9PubMed

127.

Michel P, Quenon JL, Djihoud A, et al. French national survey of inpatient adverse events prospectively assessed with ward staff. Qual Saf Health Care 2007; 16(5): 369–77PubMed

128.

Sari AB, Sheldon TA, Cracknell A, et al. Extent, nature and consequences of adverse events: results of a retrospective casenote review in a large NHS hospital. Qual Saf Health Care 2007; 16(6): 434–9PubMed

129.

Woods DM, Holl JL, Klein JD, et al. Patient safety problems in adolescent medical care. J Adolesc Health 2006; 38(1): 5–12PubMed

130.

Rothschild JM, Landrigan CP, Cronin JW, et al. The Critical Care Safety Study: the incidence and nature of adverse events and serious medical errors in intensive care. Crit Care Med 2005; 33(8): 1694–700PubMed

131.

Woods D, Thomas E, Holl J, et al. Adverse events and preventable adverse events in children. Pediatrics 2005; 115(1): 155–60PubMed

132.

Davis P, Lay-Yee R, Briant R, et al. Adverse events in New Zealand public hospitals, II: preventability and clinical context. N Z Med J 2003; 116(1183): U624PubMed

133.

Darchy B, Le Miere E, Figueredo B, et al. Iatrogenic diseases as a reason for admission to the intensive care unit: incidence, causes, and consequences. Arch Intern Med 1999; 159(1): 71–8PubMed

134.

Hallas J, Harvald B, Gram LF, et al. Drug related hospital admissions: the role of definitions and intensity of data collection, and the possibility of prevention. J Intern Med 1990; 228(2): 83–90PubMed

135.

Hallas J, Harvald B, Worm J, et al. Drug related hospital admissions: results from an intervention program. Eur J Clin Pharmacol 1993; 45(3): 199–203PubMed

136.

Hallas J, Gram LF, Grodum E, et al. Drug related admissions to medical wards: a population based survey. Br J Clin Pharmacol 1992; 33(1): 61–8PubMed

137.

Hoonhout LHF, De Bruijne MC, Wagner C, et al. Nature, occurrence and consequences of medication-related adverse events during hospitalization: a retrospective chart review in the Netherlands. Drug Saf 2010; 33(10): 853–64PubMed

138.

Pattanaik S, Dhamija P, Malhotra S, et al. Evaluation of cost of treatment of drug-related events in a tertiary care public sector hospital in Northern India: a prospective study. Br J Clin Pharmacol 2009; 67(3): 363–9PubMed

139.

Rogers S, Wilson D, Wan S, et al. Medication-related admissions in older people: a cross-sectional, observational study. Drugs Aging 2009; 26(11): 951–61PubMed

140.

Al-Olah YH, Al Thiab KM. Admissions through the emergency department due to drug-related problems. Ann Saudi Med 2008; 28(6): 426–9PubMed

141.

Leendertse AJ, Egberts AC, Stoker LJ, et al. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008; 168(17): 1890–6PubMed

142.

Witherington EMA, Pirzada OM, Avery AJ. Communication gaps and readmissions to hospital for patients aged 75 years and older: observational study. Qual Saf Health Care 2008; 17(1): 71–5PubMed

143.

Zed PJ, Abu-Laban RB, Balen RM, et al. Incidence, severity and preventability of medication-related visits to the emergency department: a prospective study. CMAJ 2008; 178(12): 1563–9PubMed

144.

Zargarzadeh AH, Emami MH, Hosseini F. Drug-related hospital admissions in a generic pharmaceutical system. Clin Exp Pharmacol Physiol 2007; 34(5–6): 494–8PubMed

145.

Baena MI, Faus MJ, Fajardo PC, et al. Medicine-related problems resulting in emergency department visits. Eur J Clin Pharmacol 2006; 62(5): 387–93PubMed

146.

Samoy LJ, Zed PJ, Wilbur K, et al. Drug-related hospitalizations in a tertiary care internal medicine service of a Canadian hospital: a prospective study. Pharmacotherapy 2006; 26(11): 1578–86PubMed

147.

Easton KL, Chapman CB, Brien JA. Frequency and characteristics of hospital admissions associated with drug-related problems in paediatrics. Br J Clin Pharmacol 2004; 57(5): 611–5PubMed

148.

Howard RL, Avery AJ, Howard PD, et al. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Health Care 2003; 12(4): 280–5PubMed

149.

Koh Y, Fatimah BM, Li SC. Therapy related hospital admission in patients on polypharmacy in Singapore: a pilot study. Pharm World Sci 2003; 25(4): 135–7PubMed

150.

Ng D, Cosh DG, Harris J, et al. Unplanned medication-related admissions to an acute care general teaching hospital. Aust J Hosp Pharm 1999; 29(2): 84–7

151.

Tafreshi MJ, Melby MJ, Kaback KR, et al. Medication-related visits to the emergency department: a prospective study. Ann Pharmacother 1999; 33(12): 1252–7PubMed

152.

Easton KL, Parsons BJ, Starr M, et al. The incidence of drug-related problems as a cause of hospital admissions in children. Med J Aust 1998; 169(7): 356–9PubMed

153.

Cunningham G, Dodd TR, Grant DJ, et al. Drug-related problems in elderly patients admitted to Tayside hospitals, methods for prevention and subsequent reassessment. Age Ageing 1997; 26(5): 375–82PubMed

154.

Dartnell JG, Anderson RP, Chohan V, et al. Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs. Med J Aust 1996; 164(11): 659–62PubMed

155.

Dennehy CE, Kishi DT, Louie C. Drug-related illness in emergency department patients. Am J Health Syst Pharm 1996; 53(12): 1422–6PubMed

156.

Nelson KM, Talbert RL. Drug-related hospital admissions. Pharmacotherapy 1996; 16(4): 701–7PubMed

157.

Courtman BJ, Stallings SB. Characterization of drug-related problems in elderly patients on admission to a medical ward. Can J Hosp Pharm 1995; 48(3): 161–6PubMed

158.

Hallas J, Worm J, Beck-Nielsen J, et al. Drug related events and drug utilization in patients admitted to a geriatric hospital department. Dan Med Bull 1991; 38(5): 417–20PubMed

159.

Dubois RW, Brook RH. Preventable deaths: who, how often, and why? Ann Intern Med 1988; 109(7): 582–9PubMed

160.

Hiatt HH, Barnes BA, Brennan TA, et al. A study of medical injury and medical malpractice. N Engl J Med 1989; 321(7): 480–4PubMed

161.

Wilson RM, Runciman WB, Gibberd RW, et al. The Quality in Australian Health Care Study. Med J Aust 1995; 163(9): 458–71PubMed

162.

Davis P, Lay-Yee R, Briant R, et al. Adverse events in New Zealand public hospitals: principal findings from a national survey —occasional paper no 3. Wellington: Ministry of Health, 2001

163.

Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990; 47(3): 533–43PubMed

164.

Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992; 27(6): 538PubMed

165.

Imbs JL, Pletan Y, Spriet A. Assessment of preventable iatrogenic drug therapy: methodology —round table no. 2 at Giens XIII [in French]. Therapie 1998; 53(4): 365–70PubMed

166.

Livio F, Buclin T, Yersin B, et al. Hospitalisations pour effet indésirable médicamenteux. Raison de Santé No. 23. Lausanne: Hospices Cantonaux, 1998

167.

Baena MI, Marin R, Martinez-Olmos J, et al. New criteria of assessing preventability of drug-related problems: an updated review based on the experience with 2558 people [in Spanish]. Pharm Care Esp 2002; 4: 393–6

168.

Lau PM, Stewart K, Dooley MJ. Comment: hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother 2003; 37(2): 303–4PubMed

169.

Olivier P, Caron J, Haramburu F, et al. Validation of a measurement scale: example of a French Adverse Drug Reactions Preventability Scale [in French]. Therapie 2005; 60(1): 39–45PubMed

170.

Zegers M, de Bruijne MC, Wagner C, et al. The inter-rater agreement of retrospective assessments of adverse events does not improve with two reviewers per patient record. J Clin Epidemiol 2010; 63(1): 94–102PubMed

171.

Kunac DL, Reith DM, Kennedy J, et al. Inter-and intra-rater reliability for classification of medication related events in paediatric inpatients. Qual Saf Health Care 2006; 15(3): 196–201PubMed

172.

Michel P, Quenon JL, de Sarasqueta AM, et al. Comparison of three methods for estimating rates of adverse events and rates of preventable adverse events in acute care hospitals. BMJ 2004; 328(7433): 199PubMed

173.

Thomas EJ, Lipsitz SR, Studdert DM, et al. The reliability of medical record review for estimating adverse event rates. Ann Intern Med 2002; 136(11): 812–6PubMed

174.

Altman DG. Some common problems in medical research. In: Altman DG, editor. Practical statistics for medical research. 1st ed. Boca Raton (FL): Chapman & Hall/CPC, 1991: 396–439

175.

Snyder RA, Abarca J, Meza JL, et al. Reliability evaluation of the adapted national coordinating council medication error reporting and prevention (NCC MERP) index. Pharmacoepidemiol Drug Saf 2007; 16(9): 1006–13PubMed

176.

Hayward RA, Hofer TP. Estimating hospital deaths due to medical errors: preventability is in the eye of the reviewer. JAMA 2001; 286(4): 415–20PubMed

177.

Caplan RA, Posner KL, Cheney FW. Effect of outcome on physician judgments of appropriateness of care. JAMA 1991; 265(15): 1957–60PubMed

178.

Aronson JK, Ferner RE. Preventability of drug-related harms-part II: proposed criteria, based on frameworks that classify adverse drug reactions. Drug Saf 2010; 33(11): 995–1002PubMed

179.

Streiner DL, Norman GR. Scaling responses. In: Streiner DL, Norman GR, editors. Health measurement scales-a practical guide to their development and use. 3rd ed. New York: Oxford University Press, 2003: 29–60

180.

Brennan TA, Localio RJ, Laird NL. Reliability and validity of judgments concerning adverse events suffered by hospitalized patients. Med Care 1989; 27(12): 1148–58PubMed

181.

Bryant GD, Norman GR. Expressions of probability: words and numbers. N Engl J Med 1980; 302(7): 411PubMed

182.

Williams SD, Ashcroft DM. Medication errors: how reliable are the severity ratings reported to the national reporting and learning system? Int J Qual Health Care 2009; 21(5): 316–20PubMed

183.

Localio AR, Weaver SL, Landis JR, et al. Identifying adverse events caused by medical care: degree of physician agreement in a retrospective chart review. Ann Intern Med 1996; 125(6): 457–64PubMed

184.

Hofer TP, Bernstein SJ, DeMonner S, et al. Discussion between reviewers does not improve reliability of peer review of hospital quality. Med Care 2000; 38(2): 152–61PubMed

185.

MacKenzie EJ, Steinwachs DM, Bone LR, et al. Interrater reliability of preventable death judgments. The Preventable Death Study Group. J Trauma 1992; 33(2): 292–302PubMed

186.

Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007; 4(10): e297PubMed

187.

International Society for Pharmacoepidemiology (ISPE). Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf 2008; 17(2): 200–8

188.

Ferner RE, Aronson JK. Clarification of terminology in medication errors: definitions and classification. Drug Saf 2006; 29(11): 1011–22PubMed

189.

World Health Organization. WHO patient safety research: better knowledge for safer care. Geneva: World Health Organization, 2009

190.

Expert Group on Safe Medication Practices. Creation of a better medication safety culture in Europe: building up safe medication practices. Strasbourg: Council of Europe, 2006

191.

European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. EMA/489873/2008: ENCePP code of conduct for scientific independence and transparency in the conduct of pharmacoepidemiological and pharmacovigilance studies. London: European Medicines Agency, 2010

192.

World Health Organization. World alliance for patient safety: forward programme 2008–2009. 1st ed. Geneva: World Health Organization, 2008

193.

Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356(9237): 1255–9PubMed

194.

Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring: cost and benefit considerations, part II —cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf 1997; 6 Suppl. 3: S79–90PubMed

Titel: Methods for Assessing the Preventability of Adverse Drug Events
A Systematic Review
verfasst von: Katja Marja Hakkarainen
Karolina Andersson Sundell
Max Petzold
Staffan Hägg
Publikationsdatum: 01.02.2012
Verlag: Springer International Publishing
Erschienen in: Drug Safety / Ausgabe 2/2012
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.2165/11596570-000000000-00000

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2012

Effects of Proton Pump Inhibitors on Platelet Function in Patients Receiving Clopidogrel

Trends in Hepatic Injury Associated with Unintentional Overdose of Paracetamol (Acetaminophen) in Products with and without Opioid

Erratum to Trends in hepatic injury associated with unintentional overdose of paracetamol (acetaminophen) in products with and without opioid: an analysis using the National Poison Data System of the American Association of Poison Control Centers, 2000–7

Selected National Pharmacovigilance Websites

Risk of Cardiac Valve Regurgitation with Dopamine Agonist use in Parkinson’s Disease and Hyperprolactinaemia

Risk Evaluation and Mitigation Strategies (REMS)